Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15195448 | 1.00 | LMNA (0.52) | LMNAKDM4EL3MBTL1AOC3RIPK1 | |
| SCHEMBL19896651 | 0.88 | TAAR1 (0.39) | LMNAKDM4EL3MBTL1AOC3TSHR | |
| SCHEMBL11673244 | 0.83 | LMNA (0.41) | LMNAKDM4EL3MBTL1AOC3RIPK1 | |
| SCHEMBL21935479 | 0.80 | TAAR1 (0.54) | LMNAKDM4ETSHRSMN1; SMN2KMT2A | |
| SCHEMBL4169733 | 0.79 | LMNA (0.54) | LMNAKDM4EL3MBTL1AOC3RIPK1 | |
| SCHEMBL27692795 | 0.78 | RIPK1 (0.50) | LMNAKDM4EL3MBTL1AOC3RIPK1 | |
| SCHEMBL2496078 | 0.78 | RIPK1 (0.50) | LMNAKDM4EL3MBTL1AOC3RIPK1 | |
| SCHEMBL24240337 | 0.78 | CYP19A1 (0.41) | KDM4EAOC3TSHRSMN1; SMN2KMT2A | |
| SCHEMBL12236986 | 0.78 | TACR1 (0.40) | LMNAKDM4EL3MBTL1AOC3TSHR | |
| SCHEMBL9644848 | 0.78 | PYCR1 (0.44) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118619855-A | Amide or ester compound or derivative thereof and application thereof | 暨南大学 | 2024-09-10 | — | — | CN | disclosed |
| US-11084834-B2 | Chiral phosphoramidimidates and derivatives thereof | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2021-08-10 | — | — | US | disclosed |
| EP-3344639-B1 | CHIRAL PHOSPHORAMIDIMIDATES AND DERIVATIVES THEREOF | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2020-06-24 | — | — | EP | disclosed |
| US-9981923-B2 | 1,2,3 Triazole antifungal agents and preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2018-05-29 | — | — | US | disclosed |
| US-9981923-B2 | 1,2,3 Triazole antifungal agents and preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2018-05-29 | — | — | US | disclosed |
| US-9783561-B2 | Chiral imidodiphosphates and derivatives thereof | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2017-10-10 | — | — | US | disclosed |
| US-9783561-B2 | Chiral imidodiphosphates and derivatives thereof | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2017-10-10 | — | — | US | disclosed |
| EP-2802561-B1 | CHIRAL IMIDODIPHOSPHATES AND DERIVATIVES THEREOF | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2017-07-26 | — | — | EP | disclosed |
| US-20170197924-A1 | Novel 1,2,3 Triazole Antifungal Agents and Preparation Thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-07-13 | — | — | US | disclosed |
| US-20170197924-A1 | Novel 1,2,3 Triazole Antifungal Agents and Preparation Thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-07-13 | — | — | US | disclosed |
| EP-0820809-A1 | TITANIUM CATALYST, ORGANOTITANIUM REACTION REAGENT, PROCESSES FOR PRODUCING THESE, AND METHOD OF REACTION USING THESE | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1998-01-28 | — | — | EP | disclosed |
| US-5523495-A | REACTING KETONE OR ALDEHYDE WITH A DIHALOPROPENE IN PRESENCE OF ZINC POWDER, WATER AND ACID YIELDS A HALOALLYLCARBINOL WHICH CAN BE DEHALOGENATED WITH A BASE, NONEXPLOSIVE | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1996-06-04 | — | — | US | disclosed |
| EP-0404077-B1 | Process for producing propargylcarbinol compounds | SUMITOMO CHEMICAL CO (JP) | 1994-06-01 | — | — | EP | disclosed |
| US-5258529-A | Dehydrohalogenation of corresponding alkene | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-11-02 | — | — | US | disclosed |
| EP-0404077-A1 | Process for producing propargylcarbinol compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1990-12-27 | — | — | EP | disclosed |
| US-4179561-A | REACTING A 3-DIAZOOXINDOLE WITH A SUBSTITUTED ACETYLENE | E. R. SQUIBB & SONS, INC. (US) | 1979-12-18 | — | — | US | disclosed |
| US-4168367-A | BY-PRODUCT INHIBITION, CROSSLINKING | PLASTICS ENGINEERING COMPANY (US) | 1979-09-18 | — | — | US | disclosed |
| US-4166168-A | POLYMERIZATION PRODUCTS OF ACETYLENE-TERMINATED POLYIMIDE DERIVATIVES | PLASTICS ENGINEERING COMPANY (US) | 1979-08-28 | — | — | US | disclosed |
| US-4112096-A | ANTIALLERGENS | E. R. SQUIBB & SONS, INC. (US) | 1978-09-05 | — | — | US | disclosed |
| US-4076818-A | ANTIALLERGENS | E. R. SQUIBB & SONS, INC. (US) | 1978-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084834-B2 | Chiral phosphoramidimidates and derivatives thereof | PLCB3, PIN1, PLCD1 | LMNA 4608/4885KDM4E 4152/4885L3MBTL1 2951/4885 |
| US-20170197924-A1 | Novel 1,2,3 Triazole Antifungal Agents and Preparation Thereof | ERG28, CYP51A1, CYP2F1 | LMNA 4224/4885KDM4E 3838/4885L3MBTL1 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.